Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268–1274.
228.
Mizuuchi H, Nasim S, Kudo R, et al. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 1992;52:2777–2781.
229.
Fujimoto I, Shimizu Y, Hirai Y, et al. Studies on ras oncogene activation in endometrial carcinoma. Gynecol Oncol 1993;48:196–202.
230.
Semczuk A, Berbec H, Kostuch M, et al. K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients’ outcome. J Cancer Res Clin Oncol 1998;124:695–700.
231.
Sonoda G, du Manoir S, Godwin AK, et al. Detection of DNA gains and losses in primary endometrial carcinomas by comparative genomic hybridization. Genes Chromosomes Cancer 1997;18:115– 125.
232.
Niederacher D, An H-X, Cho Y-J, et al. Mutations and amplification of oncogenes in endometrial cancer. Oncology 1999;56:59–65.
233.
Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177–185.
234.
Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. PNAS 2003;100:5908–5913.
235.
Tashiro H, Lax SF, Gaudin PB, et al. Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 1997;150:75– 79.
236.
Saffari B, Jones LA, Elnaggar A, et al. Amplification and overexpression of Her-2/Neu (C-Erbb2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55:5693–5698.
237.
Halperin R, Zehavi S, Habler L, et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001;22:122–126.
238.
Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15–21.
239.
Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179–185.
240.
Cianciulli AM, Guadagni F, Marzano R, et al. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. J Exp Clin Cancer Res 2003;22:265–271.
241.